Cargando…

COVID-19 vaccine safety

In response to the SARS-CoV-2 outbreak, and the resulting COVID-19 pandemic, a global competition to develop an anti-COVID-19 vaccine has ensued. The targeted time frame for initial vaccine deployment is late 2020. The present article examines whether short-term, mid-term, and long-term vaccine safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostoff, Ronald N., Briggs, Michael B., Porter, Alan L., Spandidos, Demetrios A., Tsatsakis, Aristidis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521561/
https://www.ncbi.nlm.nih.gov/pubmed/33000193
http://dx.doi.org/10.3892/ijmm.2020.4733
_version_ 1783588007296630784
author Kostoff, Ronald N.
Briggs, Michael B.
Porter, Alan L.
Spandidos, Demetrios A.
Tsatsakis, Aristidis
author_facet Kostoff, Ronald N.
Briggs, Michael B.
Porter, Alan L.
Spandidos, Demetrios A.
Tsatsakis, Aristidis
author_sort Kostoff, Ronald N.
collection PubMed
description In response to the SARS-CoV-2 outbreak, and the resulting COVID-19 pandemic, a global competition to develop an anti-COVID-19 vaccine has ensued. The targeted time frame for initial vaccine deployment is late 2020. The present article examines whether short-term, mid-term, and long-term vaccine safety can be achieved under such an accelerated schedule, given the myriad vaccine-induced mechanisms that have demonstrated adverse effects based on previous clinical trials and laboratory research. It presents scientific evidence of potential pitfalls associated with eliminating critical phase II and III clinical trials, and concludes that there is no substitute currently available for long-term human clinical trials to ensure long-term human safety.
format Online
Article
Text
id pubmed-7521561
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-75215612020-10-01 COVID-19 vaccine safety Kostoff, Ronald N. Briggs, Michael B. Porter, Alan L. Spandidos, Demetrios A. Tsatsakis, Aristidis Int J Mol Med Articles In response to the SARS-CoV-2 outbreak, and the resulting COVID-19 pandemic, a global competition to develop an anti-COVID-19 vaccine has ensued. The targeted time frame for initial vaccine deployment is late 2020. The present article examines whether short-term, mid-term, and long-term vaccine safety can be achieved under such an accelerated schedule, given the myriad vaccine-induced mechanisms that have demonstrated adverse effects based on previous clinical trials and laboratory research. It presents scientific evidence of potential pitfalls associated with eliminating critical phase II and III clinical trials, and concludes that there is no substitute currently available for long-term human clinical trials to ensure long-term human safety. D.A. Spandidos 2020-11 2020-09-18 /pmc/articles/PMC7521561/ /pubmed/33000193 http://dx.doi.org/10.3892/ijmm.2020.4733 Text en Copyright: © Kostoff et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kostoff, Ronald N.
Briggs, Michael B.
Porter, Alan L.
Spandidos, Demetrios A.
Tsatsakis, Aristidis
COVID-19 vaccine safety
title COVID-19 vaccine safety
title_full COVID-19 vaccine safety
title_fullStr COVID-19 vaccine safety
title_full_unstemmed COVID-19 vaccine safety
title_short COVID-19 vaccine safety
title_sort covid-19 vaccine safety
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521561/
https://www.ncbi.nlm.nih.gov/pubmed/33000193
http://dx.doi.org/10.3892/ijmm.2020.4733
work_keys_str_mv AT kostoffronaldn covid19vaccinesafety
AT briggsmichaelb covid19vaccinesafety
AT porteralanl covid19vaccinesafety
AT spandidosdemetriosa covid19vaccinesafety
AT tsatsakisaristidis covid19vaccinesafety